-
公开(公告)号：US20210163466A1
公开(公告)日：2021-06-03
申请号：US16614877
申请日：2018-05-21
发明人： Masaki ASADA , Kousuke TANI , Satonori HIGUCHI
IPC分类号： C07D417/12 , C07D413/12 , C07D403/12 , C07D401/12 , C07D403/14 , C07D405/12 , A61K45/06
摘要： A compound represented by general formula (I): (wherein in the formula, all the symbols have the same meanings as those described in the specification), or a pharmaceutically acceptable salt thereof is useful as a medicament's active ingredient having an EP4 receptor antagonistic activity, in preventing and/or treating disease caused by activation of an EP4 receptor.
-
公开(公告)号：US20180319764A1
公开(公告)日：2018-11-08
申请号：US16039245
申请日：2018-07-18
发明人： Masaki ASADA , Kousuke TANI , Masaya HIROBE , Satonori HIGUCHI , Kazuhiro FUCHIBE , Ryo OIKAWA , Tohru KOTANI , Hirotsugu TAKANO
IPC分类号： C07D311/96 , C07D231/40 , C07D405/14 , A61K31/496 , A61K45/06 , C07C255/60 , C07D213/40 , C07D417/04 , C07D401/04 , C07D405/04 , C07D409/04 , C07D413/04 , A61K9/20 , C07D213/56 , C07D498/04 , C07D471/04 , C07D417/12 , C07D413/12 , C07D409/12 , C07D407/12 , C07D405/12 , C07D231/12 , C07D307/94 , C07C255/63 , A61K33/24 , A61K31/5383 , A61K31/506 , A61K31/501 , A61K31/497 , A61K31/453 , A61K31/4439 , A61K31/4433 , A61K31/4406 , A61K31/437 , A61K31/427 , A61K31/4245 , A61K31/422 , A61K31/4192 , A61K31/4155 , A61K31/415 , A61K31/4025 , A61K31/397 , A61K31/381 , A61K31/352 , A61K31/343 , A61K31/277 , A61K45/00 , A61K39/395 , A61K31/4427
摘要： A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
-
公开(公告)号：US20180002308A1
公开(公告)日：2018-01-04
申请号：US15542216
申请日：2016-01-08
发明人： Masaki ASADA , Kousuke TANI , Masaya HIROBE , Satonori HIGUCHI , Kazuhiro FUCHIBE , Ryo OIKAWA , Tohru KOTANI , Hirotsugu TAKANO
IPC分类号： C07D311/96 , C07D417/12 , C07D417/04 , C07D413/12 , C07D413/04 , C07D409/04 , C07D407/12 , C07D405/14 , C07D405/12 , C07D405/04 , C07D401/04 , C07D231/40 , C07D213/40 , C07C255/60 , A61K45/06 , A61K31/5383 , A61K31/501 , A61K31/496 , A61K31/4439 , A61K31/4433 , A61K31/4427 , A61K31/4406 , A61K31/427 , A61K31/4245 , A61K31/422 , A61K31/4192 , A61K31/4155 , A61K31/415 , A61K31/4025 , A61K31/397 , A61K31/381 , A61K31/352 , A61K31/277 , A61K9/20 , C07D498/04 , C07C2603/94
CPC分类号： C07D311/96 , A61K9/20 , A61K31/277 , A61K31/343 , A61K31/352 , A61K31/381 , A61K31/397 , A61K31/4025 , A61K31/415 , A61K31/4155 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4406 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/453 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K33/24 , A61K39/395 , A61K45/00 , A61K45/06 , C07C255/60 , C07C255/63 , C07C2603/94 , C07D213/40 , C07D213/56 , C07D231/12 , C07D231/40 , C07D307/94 , C07D401/04 , C07D405/04 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/04 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D498/04
摘要： A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
-
公开(公告)号：US20220204468A1
公开(公告)日：2022-06-30
申请号：US17695796
申请日：2022-03-15
IPC分类号： C07D309/06 , A61P25/20 , C07C233/81 , C07C235/64 , C07C327/48
摘要： An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
-
公开(公告)号：US20220033371A1
公开(公告)日：2022-02-03
申请号：US17276284
申请日：2019-09-19
IPC分类号： C07D309/06 , C07C235/64 , C07C233/81 , C07C327/48 , A61P25/20
摘要： An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
-
-
-
-
搜索结果
5 条记录 (耗时 0.023 秒)
